Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03799718

Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS

Multiple Sclerosis, Chronic Progressive Clinical Trial

Official title:
A Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MS

Clinical Trial Summary

A multidose open-label study with autologous Mesenchymal Stromal Stem Cells Secreting Neurotrophic Factors (MSC-NTF cells) involving 20 participants with progressive MS at multiple investigational study sites.

Clinical Trial Description

An open-label study with a single treatment arm involving 20 participants with progressive MS at multiple investigational study sites. After providing informed consent, participants meeting the inclusion and exclusion criteria will be randomized and approximately 4 weeks later will undergo a bone-marrow aspiration (BMA). Each participants will receive three Intrathecal cell transplantations within 16 weeks and will be followed for 12 weeks for safety and efficacy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03799718
Study type Interventional
Source Brainstorm-Cell Therapeutics
Contact
Status Completed
Phase Phase 2
Start date March 13, 2019
Completion date March 30, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Completed NCT01188811 - Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Phase 2/Phase 3
Recruiting NCT05562414 - Transient and Immediate Motor Effects of Exercise in Progressive Multiple Sclerosis N/A
Completed NCT02545959 - Intrathecal Rituximab in Progressive Multiple Sclerosis Phase 2
Completed NCT01436838 - China Betaferon Adherence, Coping and Nurse Support Study N/A
Recruiting NCT00220493 - Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients Phase 1
Recruiting NCT05496881 - Exercise Effects in Multiple Sclerosis N/A
Recruiting NCT02903537 - Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS) Phase 1
Temporarily not available NCT02606929 - Use of Well Known Drugs for New Destination - MS Improvement (MSNT) Phase 0
Completed NCT03424538 - The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients N/A
Completed NCT02403570 - Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis
Active, not recruiting NCT04993274 - Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
Active, not recruiting NCT00411723 - Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects With Multiple Sclerosis Phase 1
Completed NCT00241254 - Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Phase 3
Completed NCT02632591 - Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment Phase 1
Not yet recruiting NCT05385731 - MUSCLE - Nordic Walking in MUltiple SCLErosis N/A
Recruiting NCT05359653 - Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Phase 1/Phase 2
Completed NCT04550650 - Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients N/A
Active, not recruiting NCT03114293 - Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS N/A